The Relationship Between The Expression Of CerbB-2, Ki-67,PARP-1before And After Neoadjuvant Chemotherapy In Breast Cancer And Response To Neoadjuvant Chemotherapy

Objective:In order to provide experimental evidence in finding biological factors for predicting response to neoadjuvant chemotherapy in breast cancer, we explore the expression of CerbB-2, Ki-67, PARP-1before and after the neoadjuvant chemotherapy in breast cancer and the relationship between the changes in biological marker expression and response to neoadjuvant chemotherapy.Methods:This study selected65patients with stage II B~III invasive breast cancer who are diagnosed by pathology using12G disposable biopsy needle from June2010to July2011in our Breast Surgery. These patients received4cycles neoadjuvant TEC (docetaxel, epirubicin, and cyclophosphamide) chemotherapy (3cases didn't finish four cycles chemotherapy). We evaluated response of neoadjuvant chemotherapy according to RECIST(response evaluation criteria in solid tumors). After the operation (2patients didn't receive operation because of their disease progression), we found12patients got pathological complete response by HE (Hemetoxylin and Eosin) staining examine. The expression of C-erbB-2, Ki-67, PARP-1in these tissues before and after neoadjuvant chemotherapy was examined by immunohisto chemistry with mouse anti-human C-erbb-2monoclonal antibody, mouse anti-human Ki-67monoclonal antibody and mouse anti-human PARP-1monoclonal antibody respectively. SPSS17.0software was well for statistical analysis.Results:1The response of neoadjuvant chemotherapy in breast cancer patients:13patients (20.97%) showed clinical complete response;33patients (53.23%) showed partial response;14patients (22.58%) showed stable disease;2patients (3.22%) showed progressive disease. The clinical efficiency was74.19%(46/62), the clinical benefit rate was96.77%(60/62). There were12patients (19.35%) got pathological complete response.2Comparing the efficiency of neoadjuvant chemotherapy in breast cancer between the patients with C-erbB-2positive and the patients with C-erbB-2negative, the difference didn't show statistical significance (X2=0.940, P=0.332); comparing the efficiency of neoadjuvant chemotherapy in breast cancer between the patients with Ki-67positive and the patients with Ki-67negative, the difference showed statistically significant (X2=6.368,P=0.012); comparing the efficiency of neoadjuvant chemotherapy in breast cancer between the patients with PARP-1positive and the patients with PARP-1negative, the difference showed statistical significance (X2=4.062, P=0.044).3The positive rates of C-erbB-2before and after neoadjuvant chemotherapy were31.3%and22.9%, the difference didn't show statistical significance (X2=0.844, P=0.358), the expression intensity of C-erbB-2before and after neoadjuvant chemotherapy didn't show significant changes (X2=2.491, P=0.477);the Ki67index before and after neoadjuvant chemotherapy were (38.29±28.82)%and (25.21±22.95)%, the difference show statistical significance (t=3.136, P=0.003); The positive rates of PARP-1before and after neoadjuvant chemotherapy were66.7%and62.5%, the difference didn't show statistical significance, but the expression intensity about PARP-1before and after neoadjuvant chemotherapy showed statistical significance(X2=8.911, P=0.03).4By the Spearmen rank correlation analysis, the changes in C-erbB-2expression before and after neoadjuvant chemotherapy had no correlation with the response to neoadjuvant chemotherapy(R=-0.104, P=0.484); the reduction of Ki-67index had weak correlation with the response to neoadjuvant chemotherapy (R=0.340,P=0.018); the reduction of the expression of PARP-1had weak correlation with the response to neoadjuvant chemotherapy(R=0.381, P=0.008). Conclusions:1C-erbB-2expression didn't show difference before and after neoadjuvant chemotherapy, so it couldn't be served as a biological factor to predict the response to neoadjuvant chemotherapy in breast cancer.2Ki-67index significantly reduced after neoadjuvant chemotherapy, so it can be a biological factor to predict the response to neoadjuvant chemotherapy in breast cancer.3PARP-1expression weakened after neoadjuvant chemotherapy, so it might be a biological factor to predict the response to neoadjuvant chemotherapy in breast cancer.